10/04/2026
Led by BGI Genomics with multiple research teams and institutes, the study shows that first-tier can be accessible, cost-effective, and clinically valuable for whole-population prenatal screening.
From Hebei Province:
🚀 Coverage: 47.1% → 93.3%
👶 Most positive cases were in non-advanced maternal age pregnancies
💰 Cost-effective at scale
👨👩👧 Paternal age also matters
⚠️ High-risk NIPT may signal adverse pregnancy outcomes
First-tier NIPT could help transform routine prenatal care.
📢 : First-Tier NIPT Shows Promise for Whole-Population Prenatal Screening
Led by BGI Genomics, together with multiple research teams and institutes, the study was published in Nature Health, revealing that as a first-tier screening approach is accessible, cost-effective, and clinically valuable.
Key takeaways from Hebei Province:
🚀 Coverage explosion: 47.1% → 93.3%
👶 Unexpected insights: Most positive cases were non-advanced maternal age pregnancies
💰 Cost-effective at scale: Outperforms traditional maternal serum screening
👨👩👧 Parental age matters: Paternal age impacts fetal aneuploidy risk too
⚠️ Early warning system: High-risk NIPT results can signal various adverse pregnancy outcomes
Why it matters: First-tier NIPT isn’t just a test—it’s a tool that could transform routine prenatal care.
Read the full study 👇
https://www.bgi.com/global/news/large-scale-implementation-of-first-tier-nipt-nature-health